Award
NIH Reporter #5U01DA063352-02
Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog overdose
Recipient
National Institute on Drug Abuse (NIDA), NIH, US
Award Amount
$2,089,891.00
Ceiling
$2,089,891.00
Awarded
August 25, 2026
Identifier
5U01DA063352-02
NIH/NIDA awarded approximately $2.09 million for clinical studies of the anti-fentanyl monoclonal antibody CSX-1004 to evaluate its safety, pharmacokinetics, and efficacy from 2025 to 2028.
Description
The project involves clinical studies of a monoclonal antibody (CSX-1004) targeting fentanyl and analogs. The project aims to evaluate safety, pharmacokinetics, and efficacy. The project is funded by NIH/NIDA with a budget of approximately $2.09 million. The project duration is from September 2025 to July 2028.